Fibrates and emerging therapies like pemafibrate lower serum triglycerides and raise HDL cholesterol, though their use with statins requires caution due to an enhanced risk of myopathy.
This review highlights the evolving landscape of hypertriglyceridemia management, noting the myopathy risks of older fibrates and the potential of newer agents like pemafibrate.
Hypertriglyceridemia therapy is essential for preventing cardiovascular diseases. Fibrates belong to an important class of lipid-lowering drugs useful for the management of dyslipidaemia. By acting on the peroxisome proliferator-activated receptor (PPAR)-α, these drugs lower serum triglyceride levels and raise high-density lipoprotein cholesterol. Fibrate monotherapy is associated with a risk of myopathy and this risk is enhanced when these agents are administered together with statins. However, whereas gemfibrozil can increase plasma concentrations of statins, fenofibrate has less influence on the pharmacokinetics of statins. Pemafibrate is a new PPAR-α-selective drug considered for therapy, and clinical trials are ongoing. Apart from this class of drugs, new therapies have emerged with different mechanisms of action to reduce triglycerides and the risk of cardiovascular diseases.
Canfora et al. (Sun,) conducted a review in Hypertriglyceridemia. Hypertriglyceridemia therapy (fibrates, pemafibrate) was evaluated. Fibrates and emerging therapies like pemafibrate lower serum triglycerides and raise HDL cholesterol, though their use with statins requires caution due to an enhanced risk of myopathy.